Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Vascular Surgery, University of Arizona, Tucson, Arizona.
Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Arturo Duperier 4, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Melchor Fernández Almagro, Madrid, Spain.
J Am Coll Cardiol. 2019 Dec 24;74(25):3124-3135. doi: 10.1016/j.jacc.2019.10.036.
Macrophages and fibroblasts are 2 major cell types involved in healing after myocardial infarction (MI), contributing to myocardial remodeling and fibrosis. Post-MI fibrosis progression is characterized by a decrease in cardiac macrophage content.
This study explores the potential of macrophages to express fibroblast genes and the direct role of these cells in post-MI cardiac fibrosis.
Prolonged in vitro culture of human macrophages was used to evaluate the capacity to express fibroblast markers. Infiltrating cardiac macrophages was tracked in vivo after experimental MI of LysM(Cre);ROSA26(EYFP) transgenic mice. The expression of Yellow Fluorescent Protein (YFP) in these animals is restricted to myeloid lineage allowing the identification of macrophage-derived fibroblasts. The expression in YFP-positive cells of fibroblast markers was determined in myocardial tissue sections of hearts from these mice after MI.
Expression of the fibroblast markers type I collagen, prolyl-4-hydroxylase, fibroblast specific protein-1, and fibroblast activation protein was evidenced in YFP-positive cells in the heart after MI. The presence of fibroblasts after MI was evaluated in the hearts of animals after depletion of macrophages with clodronate liposomes. This macrophage depletion significantly reduced the number of Mac3Col1A1 cells in the heart after MI.
The data provide both in vitro and in vivo evidence for the ability of macrophages to transition and adopt a fibroblast-like phenotype. Therapeutic manipulation of this macrophage-fibroblast transition may hold promise for favorably modulating the fibrotic response after MI and after other cardiovascular pathological processes.
巨噬细胞和成纤维细胞是心肌梗死后(MI)参与修复的两种主要细胞类型,它们有助于心肌重构和纤维化。MI 后纤维化进展的特征是心脏巨噬细胞含量减少。
本研究探讨巨噬细胞表达成纤维细胞基因的潜力,以及这些细胞在 MI 后心脏纤维化中的直接作用。
长时间体外培养人巨噬细胞,以评估其表达成纤维细胞标志物的能力。在 LysM(Cre);ROSA26(EYFP)转基因小鼠实验性 MI 后,在体内追踪浸润性心脏巨噬细胞。这些动物中黄色荧光蛋白(YFP)的表达仅限于髓系细胞,允许鉴定巨噬细胞衍生的成纤维细胞。在这些小鼠 MI 后心肌组织切片中,确定 YFP 阳性细胞中成纤维细胞标志物的表达。
MI 后,在心脏的 YFP 阳性细胞中证实了纤维母细胞标志物 I 型胶原、脯氨酰-4-羟化酶、纤维母细胞特异性蛋白-1 和纤维母细胞激活蛋白的表达。用氯膦酸盐脂质体耗尽巨噬细胞后,在 MI 后动物的心脏中评估了 MI 后成纤维细胞的存在。这种巨噬细胞耗竭显著减少了 MI 后心脏中 Mac3Col1A1 细胞的数量。
这些数据提供了体外和体内证据,证明巨噬细胞具有向成纤维细胞样表型转变和获得该表型的能力。对这种巨噬细胞-成纤维细胞转变的治疗干预可能为有利地调节 MI 后和其他心血管病理过程后的纤维化反应提供希望。